CSHP - California Society of Health-System Pharmacists

CSHP - California Society of Health-System Pharmacists Leaders in Wellness, Patient Safety and Optimal Use of Medications

Founded in 1962, the California Society of Health-System Pharmacists (CSHP) is a non-profit professional association established to serve the needs of hospital and health-system pharmacists. Representing over 4,500 members who practice clinical pharmacy and specialized medicine, CSHP is the largest state association for pharmacists. CSHP members share a common mission – to promote wellness, patient safety and the optimal use of medication.

CA HAN Health Update: Stay Alert for Acute Flaccid Myelitis in Late Summer and Early FallThe California Department of Pu...
08/13/2026

CA HAN Health Update: Stay Alert for Acute Flaccid Myelitis in Late Summer and Early Fall

The California Department of Public Health (CDPH) issued a Health Alert Network (HAN) Health Advisory Update about reports of acute flaccid myelitis (AFM) typically found among children. Acute flaccid myelitis (AFM) presents as sudden limb weakness and can lead to permanent paralysis. The number of reported cases of AFM in 2026 remains low in the nation and California.

The CDPH requests that healthcare providers be vigilant in recognizing acute flaccid myelitis (AFM). AFM surges have been associated with the circulation of respiratory pathogens, such as enterovirus D68 (EV‑D68). Enterovirus D68 (EV‑D68) is a virus previously associated with AFM surges, which can occur due to increased summer travel and gatherings. Additionally, consider poliovirus in patients with sudden limb weakness and obtain whole‑stool samples. Patients who are under‑vaccinated or unvaccinated for poliovirus are at risk for polio.

The CDPH recommends that healthcare providers who suspect AFM or polio consider hospitalizing the patient immediately, report patients of any age suspected to have AFM or polio as soon as possible to local health departments, and collect specimens for laboratory testing to maximize detection of possible etiologic agents.

View the CA’s HAN Health Advisory here:
https://www.cdph.ca.gov/Programs/OPA/Pages/CAHAN/Stay-Alert-for-Acute-Flaccid-Myelitis-in-Late-Summer-and-Early-Fall.aspx

🚀 Elevate Your Brand & Connect with Health-System Pharmacy Leaders Across California!Looking to expand your reach and en...
08/12/2026

🚀 Elevate Your Brand & Connect with Health-System Pharmacy Leaders Across California!

Looking to expand your reach and engage directly with key decision-makers, clinical leaders, and pharmacy practitioners? CSHP is excited to share our updated Corporate Partnership Packages and À La Carte Marketing Opportunities!

Whether you're looking for year-round, multi-tiered visibility or targeted single-channel outreach, CSHP offers customized solutions designed to meet your organization’s goals.

🔗 Explore Corporate Packages: https://www.cshp.org/CorpPartnerships

🔗 View À La Carte Marketing Options: https://www.cshp.org/MarketingOpportunities

🗓️ SEMINAR 2026 SESSION SPOTLIGHT #1 🗓️ Reproductive healthcare legislation, judicial rulings, and regulatory requireme...
08/11/2026

🗓️ SEMINAR 2026 SESSION SPOTLIGHT #1 🗓️

Reproductive healthcare legislation, judicial rulings, and regulatory requirements are changing rapidly—California pharmacists now have more authority than ever to make a difference! 💡✨

Join clinical leaders Sally Rafie, PharmD, Sarah McBane, PharmD, and Kathleen Besinque, PharmD at CSHP Seminar 2026 in Anaheim for an essential dive into reproductive health updates!

📌 What You’ll Learn:
1️⃣ CA law updates & expanded prescribing authority under AB 1503
2️⃣ Step-by-step mifepristone FDA REMS pharmacy certification & Nexplanon guidelines
3️⃣ Postpartum/OTC contraceptive coverage & health-system operational tools

Patients and providers rely on pharmacists who know the law and can deliver care without hesitation. Don’t miss out on this session and over 70+ CE offerings!

🔗 Register & view our full schedule at: https://www.cshp.org/Seminar2026

FDA Approves New Drug to Treat High CholesterolThe U.S. Food and Drug Administration (FDA) has approved a new drug to lo...
08/11/2026

FDA Approves New Drug to Treat High Cholesterol

The U.S. Food and Drug Administration (FDA) has approved a new drug to lower LDL cholesterol in adults with high cholesterol. Lipfendra (enlicitide) is a proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitor administered as an oral tablet. Lipfendra (enlicitide) is the first oral PCSK9 inhibitor used as an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C) in adults with hypercholesterolemia, including those with heterozygous familial hypercholesterolemia (HeFH).

The safety and efficacy of Lipfendra (enlicitide) were evaluated in two randomized, double-blind, placebo-controlled clinical trials involving 3,207 adults with hypercholesterolemia, including patients with and without HeFH, who were receiving maximally tolerated statin therapy. The primary endpoint in both studies was the percent change in LDL-C from baseline to Week 24 compared with placebo.

Warnings and precautions for Lipfendra (enlicitide) were similar between those treated with Lipfendra (enlicitide) and those receiving placebo. The most common adverse reactions in a study of adults with HeFH treated with Lipfendra (enlicitide) were diarrhea and dizziness.

View the FDA’s announcement here:
https://www.fda.gov/news-events/press-announcements/fda-approves-first-oral-pcsk9-inhibitor-lower-ldl-cholesterol-adults-high-cholesterol

🎓 Pharmacy Students: Elevate Your Career with CSHP! 🌟Are you looking to gain hands-on experience and build connections w...
08/10/2026

🎓 Pharmacy Students: Elevate Your Career with CSHP! 🌟

Are you looking to gain hands-on experience and build connections with senior-level pharmacy leaders? CSHP is offering an exciting, unpaid professional development opportunity for pharmacy students interested in supporting statewide, innovative initiatives!

Through the HLC California Pharmacy Consortium, you’ll work alongside key leaders tackling crucial issues shaping our profession—including reimbursement, provider status, workforce, community, and health policy.

✨ Key Details:
• Time Commitment: ~5–7 hours per week (Flexible Schedule)
• Key Benefits: Experience in project coordination, professional communication, and direct collaboration with industry leaders.
• Application Deadline: Monday, August 31

👉 How to Apply: Submit a letter of interest directly to Dr. Loriann DeMartini, CSHP CEO ([email protected]).

🗓️ UPCOMING CE WEBINAR 🗓️Ready to update your practice with the latest in cardiovascular care? Join CSHP’s New Practitio...
08/09/2026

🗓️ UPCOMING CE WEBINAR 🗓️

Ready to update your practice with the latest in cardiovascular care? Join CSHP’s New Practitioner Executive Committee (NPEC) on Thursday, August 27 for 2026 ACC/AHA Dyslipidemia Updates! 💡✨

Featuring Christian James Squires, PharmD, AAHIVP (UC Davis Health), this session will review updated lipid treatment goals, non-statin therapies, Lp(a) screening, and the PREVENT-ASCVD calculator through clinical guideline review and patient case discussions.

📌 Quick Details:
🗓️ Date: Thursday, August 27, 2026
⏰ Time: 6:00 PM – 7:00 PM PT
🎓 CE Credit: 1.0 Contact Hour (Pharmacists)
💵 Pricing: FREE for CSHP Members!

🔗 Register at: https://www.cshp.org/CSHP_Webinar8-27-2026

FDA Approves New Drug to Reduce ProteinuriaThe U.S. Food and Drug Administration (FDA) has approved a new drug to reduce...
08/08/2026

FDA Approves New Drug to Reduce Proteinuria

The U.S. Food and Drug Administration (FDA) has approved a new drug to reduce proteinuria in adults with primary immunoglobulin A nephropathy at risk for disease progression. Atacicept-vymj (Trutakna) is a B-lymphocyte stimulator (BLyS)-specific inhibitor and A Proliferation Inducing Ligand (APRIL) blocker administered as a once-weekly subcutaneous injection.

The safety and efficacy of atacicept-vymj (Trutakna) were evaluated in a randomized, double-blind, placebo-controlled clinical trial (NCT04716231) in adults with biopsy-confirmed IgA nephropathy. Patients were randomly assigned to either Trutakna 150 mg injected subcutaneously once weekly or placebo. The primary efficacy endpoint assessed the change from baseline in proteinuria after 9 months of treatment in the first 203 patients who had the opportunity to reach the month 9 visit.

Warnings and precautions for atacicept-vymj (Trutakna) include immunosuppression, increased risk of infections, and immunization risk. The most common adverse reactions (incidence ≥5% and greater than placebo) include upper respiratory tract infection, injection site reaction, and injection site erythema.

View the FDA’s announcement here:
https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-new-treatment-reduce-proteinuria-adults-primary-immunoglobulin-nephropathy

Calling all pharmacy visionaries! The deadline for CSHP’s 2026 Music Video Competition is officially ONE MONTH AWAY! ⏰As...
08/07/2026

Calling all pharmacy visionaries! The deadline for CSHP’s 2026 Music Video Competition is officially ONE MONTH AWAY! ⏰

As we gear up for Seminar 2026 at the Disneyland® Hotel in Anaheim, we want to see the real "magic" you perform every day. Show us how you are shaping the future of healthcare through high-energy, creative, and inspiring videos! 🌟💊

🏆 WHY ENTER?
✨ Seminar Glory: Your video featured on the big screen at the Seminar 2026 Awards Ceremony!
🏆 Bragging Rights: Take home the coveted traveling trophy + social media spotlight!
🙌 Showcase Your Profession: Represent your team at the largest gathering of health-system pharmacists on the West Coast!

📅 Submission Deadline: September 15, 2026

🔗 View Guidelines & Submit: https://www.cshp.org/MVC

Free CE from Medscape and MMWR: Expanded Recommendations for Use of Pneumococcal Conjugate Vaccines Among Adults Aged ≥5...
08/06/2026

Free CE from Medscape and MMWR: Expanded Recommendations for Use of Pneumococcal Conjugate Vaccines Among Adults Aged ≥50 Years: Recommendations of the Advisory Committee on Immunization Practices — United States, 2024

Medscape will be hosting a free online CE activity to discuss new guidelines to help clinicians to protect patients against invasive pneumococcal disease (IPD).

Upon completing this activity, participants will be able to assess the epidemiology of severe pneumococcal disease in the United States, evaluate different forms of pneumococcal vaccines, distinguish the vaccine schedule for pneumococcal vaccines, and analyze serotype coverage in different formulations of pneumococcal vaccine.

Pharmacists are a part of the target audience for this activity.

Valid for credit through 6/1/2027.
Registration is not required.
This event offers 0.50 contact hours in pharmacy education.

View the Medscape Activity information here:
https://www.medscape.org/viewarticle/1003219

🗳️ Meet the Candidates for the 2027 CSHP Board Election! 🗳️Your vote. Your Society. Your opportunity to shape the future...
08/05/2026

🗳️ Meet the Candidates for the 2027 CSHP Board Election! 🗳️

Your vote. Your Society. Your opportunity to shape the future of health-system pharmacy in California!

Join CSHP for our upcoming live Meet-the-Candidates virtual sessions to hear directly from those seeking to lead our Society, learn about their professional backgrounds and visions, and ask questions during our live Q&A!

👉 Register today and make an informed vote: https://www.cshp.org/Election_Bulletin2027

Address

1314 H Street, Ste 100
Sacramento, CA
95814

Opening Hours

Monday 8am - 5pm
Tuesday 8am - 5pm
Wednesday 8am - 5pm
Thursday 8am - 5pm
Friday 8am - 5pm

Telephone

+19164471033

Website

Alerts

Be the first to know and let us send you an email when CSHP - California Society of Health-System Pharmacists posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to CSHP - California Society of Health-System Pharmacists:

Shortcuts

Featured

Share

Category